Chemotherapy delivered with radiotherapy may provide benefit over and above the addition of more cell kill. This may be due to the inhibition of DNA repair by the agent or some other mechanism of tumour radiosensitization. More clinical studies are required to define the optimal combination of chemotherapy and radiotherapy and to ensure this is a selective improvement for the tumour and does not just produce additive toxicity. The approach of targeted delivery of radiosensitizing agents selectively to tumours (e.g. via liposomes) may provide therapeutic gain.
Was this article helpful?